Home / Top News / Angion Reports Positive Results from Phase 1 Healthy Volunteer Study for ANG-3070 and FDA Authorization to Initiate Phase 2 Trial in 2021
Angion Reports Positive Results from Phase 1 Healthy Volunteer Study for ANG-3070 and FDA Authorization to Initiate Phase 2 Trial in 2021
ANG-3070 was well-tolerated across dose cohorts, achieving drug exposures in humans exceeding exposures in which activity was demonstrated in animal models of proteinuric kidney diseases
Pharmacokinetic data potentially supportive of once-daily dosing
An international Phase 2 trial in patients with primary proteinuric kidney diseases will begin enrolling patients in the second half of this year
Company to host a Virtual Fibrosis R&D Day on September 20, 2021
اراب فاينانس - أخبار - الاتحاد الأوروبي يرجئ الدفع برسوم رقمية للتركيز على اتفاق الضريبة العالمية
arabfinance.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from arabfinance.com Daily Mail and Mail on Sunday newspapers.
الاتحاد الأوروبي يرجئ الدفع برسوم رقمية للتركيز على اتفاق خاص بالضريبة العالمية
aleqt.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from aleqt.com Daily Mail and Mail on Sunday newspapers.
Angion and Vifor Pharma Announce Completion of Enrollment in Phase 2 Study of ANG-3777 for Cardiac-Surgery Associated Acute Kidney Injury
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.